Evidence map›Paper›PMID 39952924›Full record

ArticleTranslational psychiatry2025

Predicting antipsychotic responsiveness using a machine learning classifier trained on plasma levels of inflammatory markers in schizophrenia.

Jie Yin Yee, Ser-Xian Phua, Yuen Mei See, Anand Kumar Andiappan, Wilson Wen Bin Goh, Jimmy Lee

Abstract read
In one paragraph

Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. From molecules to minds: Integrative multi-omics in psychiatry.Journal of mood and anxiety disorders · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Quo Vadis translational neuroscience?Translational neuroscience · 2026
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jie Yin YeeNorth Region, Institute of Mental Health, Singapore, Singapore.ORCID http://orcid.org/0000-0002-4346-445X
Ser-Xian PhuaLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Yuen Mei SeeNorth Region, Institute of Mental Health, Singapore, Singapore.
Anand Kumar AndiappanSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID http://orcid.org/0000-0002-8442-1544
Wilson Wen Bin GohLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. wilsongoh@ntu.edu.sg.
Jimmy LeeNorth Region, Institute of Mental Health, Singapore, Singapore. jimmy_lee@imh.com.sg.ORCID http://orcid.org/0000-0002-7724-7445

Funding

MOH | National Medical Research Council (NMRC) MOH-CSAINV17nov-0004National Research Foundation Singapore (National Research Foundation-Prime Minister's office, Republic of Singapore) NRF2017_SISFP09
6 · The paper itself

Abstract

We apply machine learning techniques to navigate the multifaceted landscape of schizophrenia. Our method entails the development of predictive models, emphasizing peripheral inflammatory biomarkers, which are classified into treatment response subgroups: antipsychotic-responsive, clozapine-responsive, and clozapine-resistant. The cohort comprises 146 schizophrenia patients (49 antipsychotics-responsive, 68 clozapine-responsive, 29 clozapine-resistant) and 49 healthy controls. Protein levels of immune biomarkers were quantified using the Olink Target 96 Inflammation Panel (Olink®, Uppsala, Sweden). To predict labels, a support vector machine (SVM) classifier is trained on the Olink®data matrix and evaluated via leave-one-out cross-validation. Associated protein biomarkers are identified via recursive feature elimination. We constructed three separate predictive models for binary classification: one to discern healthy controls from individuals with schizophrenia (AUC = 0.74), another to differentiate individuals who were responsive to antipsychotics (AUC = 0.88), and a third to distinguish treatment-resistant individuals (AUC = 0.78). Employing machine learning techniques, we identified features capable of distinguishing between treatment response subgroups. In this study, SVM demonstrates the power of machine learning to uncover subtle signals often overlooked by traditional statistics. Unlike t-tests, it handles multiple features simultaneously, capturing complex data relationships. Chosen for simplicity, robustness, and reliance on strong feature sets, its integration with explainable AI techniques like SHapely Additive exPlanations enhances model interpretability, especially for biomarker screening. This study highlights the potential of integrating machine learning techniques in clinical practice. Not only does it deepen our understanding of schizophrenia's heterogeneity, but it also holds promise for enhancing predictive accuracy, thereby facilitating more targeted and effective interventions in the treatment of this complex mental health disorder.

Indexed as

Antipsychotic AgentsInflammationMachine LearningSchizophreniaSupport Vector MachineAdultBiomarkersCase-Control StudiesClozapineFemaleHumansMaleMiddle AgedAntipsychotic AgentsBiomarkersClozapine

Identifiers

PMID39952924
PMCPMC11828904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.